MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease _ AntiFungal
Amplyx Pharmaceuticals
Attachments
Amplyx – Advancing Novel Therapeutic Solutions for life-threatening fungal infections.
Parents
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
*Architects: Infectious Disease _ AntiFungal
*Industry: San Diego, California
FDA _ Orphan Drug Designation
Children
2019: Amplyx has raised more than $118 million from investors, including a $67 million Series C financing round in 2017 led by Sofinnova Venture Partners.
2019: As Drug Resistance Grows, Amplyx Tests New Antifungal Drug
2019: FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
2019: Testing an experimental drug to treat life-threatening, invasive infections caused by not only strains of Candida, but also Aspergillis and rare molds
2020: Amplyx Adds Cash from Pfizer, Adage as Funding Round Tops $90M
Amplyx president and CEO Ciara Kennedy (2019)
Founded 2008
San Diego, California
Jumps
Cidara Therapeutics, Inc. (NASDAQ: CDTX)*
Pfizer Inc. (NYSE: PFE)
SCYNEXIS, Inc. (NASDAQ: SCYX)